Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance

• Published in: Clinical cancer research Vol. 24; no. 23; pp. 5841 - 5849
• Main Authors: Turner, David C., Kondic, Anna G., Anderson, Keaven M., Robinson, Andrew G., Garon, Edward B., Riess, Jonathan Wesley, Jain, Lokesh, Mayawala, Kapil, Kang, Jiannan, Ebbinghaus, Scot W., Sinha, Vikram, de Alwis, Dinesh P., Stone, Julie A.
• Format: Journal Article
• Language: English
• Published: United States 01.12.2018
• Subjects: Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Antineoplastic Agents, Immunological - adverse effects; Antineoplastic Agents, Immunological - therapeutic use; Cachexia - etiology; Cachexia - metabolism; Cachexia - mortality; Carcinoma, Non-Small-Cell Lung - complications; Carcinoma, Non-Small-Cell Lung - drug therapy; Case-Control Studies; Humans; Kaplan-Meier Estimate; Melanoma - complications; Melanoma - drug therapy; Neoplasms - complications; Neoplasms - drug therapy; Neoplasms - mortality; Proportional Hazards Models; Randomized Controlled Trials as Topic

To investigate the relationship of pembrolizumab pharmacokinetics (PK) and overall survival (OS) in patients with advanced melanoma and non-small cell lung cancer (NSCLC). PK dependencies in OS were evaluated across three pembrolizumab studies of either 200 mg or 2 to 10 mg/kg every 3 weeks (Q3W). K...